Rules of attraction: What makes pharma engage in collaboration or licensing with academia?

Edition

Rules of attraction: What makes pharma engage in collaboration or licensing with academia?

The industry-academia pair-up has been running for some time in the Life Sciences sector. Yet, the nature of their collaborations has diversified, intensified, and become more complex over the years, leading to more strategic and long-term collaborations and agreements. These changes bring to re-question what the key drivers are for pharma when engaging with academia today. Which business segments or therapeutic areas are favoured? How do pharma companies balance between collaboration, co-development, and straight licensing?

 

Moderator: Jürgen Walkenhorst, Managing Director, Life Science Nord

Stefanie Possekel

Director Technology Management
Germany
Ascenion

Gino Martini

Managing Director, Precision Health Technologies Accelerator
United Kingdom
University of Birmingham

Vishal Sahni

Director, Corporate Business Development & Strategy
Denmark
Lundbeck

Richard Reschen

Associate Director, Business Development & Licensing
United Kingdom
MSD
  • No products in the cart.